Ascendis Pharma A/S - ASND Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ascendis Pharma A/S stock.
View analyst ratings for Ascendis Pharma A/S or view top-rated stocks.

11 brokers have issued twelve-month price objectives for Ascendis Pharma A/S's shares. Their ASND stock forecasts range from $117.00 to $197.00. On average, they expect Ascendis Pharma A/S's stock price to reach $163.40 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price.
View analysts' price targets for Ascendis Pharma A/S or view top-rated stocks among Wall Street analysts.

Ascendis Pharma A/S's stock was trading at $134.53 at the start of the year. Since then, ASND stock has decreased by 29.5% and is now trading at $94.91.
View the best growth stocks for 2022 here.

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Ascendis Pharma A/S.

Ascendis Pharma A/S will be holding an earnings conference call on Wednesday, August 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Wednesday, May, 11th. The biotechnology company reported ($2.48) earnings per share for the quarter, missing analysts' consensus estimates of ($2.25) by $0.23. The biotechnology company had revenue of $7.66 million for the quarter, compared to the consensus estimate of $5.89 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 54.58% and a negative net margin of 3,281.45%. During the same period in the prior year, the company posted ($1.41) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Ascendis Pharma A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Brown Advisory Inc. (1.10%), TimesSquare Capital Management LLC (0.79%), Assenagon Asset Management S.A. (0.49%), Allspring Global Investments Holdings LLC (0.46%), Candriam S.C.A. (0.39%) and ARS Investment Partners LLC (0.28%).

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ASND stock can currently be purchased for approximately $94.91.

Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.41 billion and generates $9.20 million in revenue each year. The biotechnology company earns $-453,810,000.00 in net income (profit) each year or ($9.36) on an earnings per share basis.

Ascendis Pharma A/S employs 639 workers across the globe.

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for Ascendis Pharma A/S is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010.